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The financial burden of cancer care is a major 
barrier to achieving the best long-term outcomes. 
Cost of therapy may lead to delay or inability to 
receive the best treatment for some patients. For 
many patients with hematologic malignancies, the 
only known cure is allogeneic hematopoietic cell 
transplantation (HCT), which is a difficult and 
expensive treatment, particularly for patients 
without a matched sibling donor.
PURPOSE
PAST STUDIES
•Recent evidence demonstrates that recipients of 
allogeneic HCT have high short-term health care 
burdens. The long-term health care burden of 
allogeneic HCT survivors is not well 
understood1.
HYPOTHESIS
•We hypothesize that long-term survivors of 
allogeneic HCT after umbilical cord blood 
transplantation will have a similar burden as 
compared to those who receive grafts from 
matched siblings, while recipients of peripheral 
blood stem cell grafts from unrelated donors 
will have a higher long-term healthcare 
burden.
INTRODUCTION METHODS
•This study will determine which donor graft 
source yields best, most cost-effective 
treatment over time (up to 5 years) by reducing 
doctor visits and limiting post-HCT 
complications, including graft-versus-host 
disease and relapse.
Determining the 
healthcare burden 
of allogeneic HCT 
recipients over 
time.
* Before 100 days post-
HCT
* Between 100 days and 2 
years post-HCT
* Beyond 2 years post-
HCT
MAIN GOAL
FUTURE RESEARCH 
• Future studies will be able to take the data 
analyzed (for coming) and incorporate the 
economic burden on patients as a parameter. 
Researchers can take a similar approach with a 
larger data bank that can further support this 
study.
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